Pulmonx Corp
LUNG
Get informed when a big investor buys or sells
+ FollowMarket Cap$68.85M
Close$
Share Statistics
| Market cap | $68.85 Million |
|---|---|
| Enterprise Value | $69.49 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.33 |
| Beta | 0.31 |
| Outstanding Shares | 42,184,793 |
Return
| Return on Equity | -122.76% |
|---|---|
| Return on Assets | -41.94% |
| Return on Invested Capital | -47.27% |
Valuation & Multiples
| P/E Ratio | -1.42 |
|---|---|
| PEG | 4.22 |
| Price to Sales | 1.03 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.79 |
| Enterprise Value to EBIT | -1.56 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.81 |
| Debt to Equity | 1.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$22.39 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$21.94 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 231.96% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 107,600▼ 16.72% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 75.78%▼ 3.85% |
|---|---|
| Total Invested | $40.96M▼ 42.78% |
| Investors Holding | 115▼ 1.00% |
ESG Score
No data
About Pulmonx Corp
220 employeesPulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System...